432 filings
Page 6 of 22
UPLOAD
0nz2w
10 May 11
Letter from SEC
12:00am
8-K
by34bmk2m
28 Apr 11
Human Genome Sciences Announces First Quarter 2011 Financial Results and Key Developments
12:00am
DEFA14A
nn1dh8s s4gu8m2z
27 Apr 11
Additional proxy soliciting materials
12:00am
8-K
nl0mp2m
14 Apr 11
Human Genome Sciences Updates Investors on Progress of Benlysta® Launch and Future Priorities
12:00am
DEFA14A
ej7sdn80
30 Mar 11
Additional proxy soliciting materials
12:00am
CT ORDER
8bfmcgt sf6tp
22 Mar 11
Confidential treatment order
12:00am
8-K
gnmyly6zjkx1cf4c4f
14 Mar 11
Departure of Directors or Certain Officers
12:00am
8-K
7b4h6gu
10 Mar 11
Human Genome Sciences and Glaxosmithkline Announcefda Approval of Benlysta® (Belimumab) for Treatment of Systemic Lupus Erythematosus
12:00am
8-K
yncdwfr2 t7k65u
24 Feb 11
Human Genome Sciences Announces Fourth-quarter and Full-year Financial Results and Key Developments
12:00am
8-K
bipgh zi7
21 Jan 11
Departure of Directors or Certain Officers
12:00am
8-K
lpoxhz
10 Jan 11
Human Genome Sciences Reports Progress Toward Sustainable Revenues and Announces 2011 Goals at Jpmorgan Healthcare Conference
12:00am
8-K
0ymmp4r5
14 Dec 10
Departure of Directors or Certain Officers
12:00am
8-K
002q 9d8uwdqpql
8 Nov 10
Regulation FD Disclosure
12:00am
8-K
sz66n1u4p64knidux
27 Oct 10
Human Genome Sciences Announces Third Quarter 2010 Financial Results and Key Developments
12:00am
8-K
ey4g9t er
6 Oct 10
Amendments to Articles of Incorporation or Bylaws
12:00am
8-K
fe0pjgu5vra 2c5s
13 Sep 10
Regulation FD Disclosure
12:00am